EMA Grants BioMarin Priority Medicine Support for Hemophilia Therapy

BioMarin received a priority medicine designation from the European Medicines Agency for its gene therapy treatment for hemophilia A.

The therapy, BMN 270, is designed to alter a genetic problem by adding a corrected copy of the defective gene. In this case, it would be factor VIII, a clotting protein.